# GLP Ranked — full site digest for machine readers
Generated from the live content manifests. Data current as of: 2026-07-24.

## Evidence vocabulary used across this site
- verified-by-us: we archived the source and a named reviewer reproduced the exact claim. Currently 0 claims qualify.
- primary-source-linked: an authoritative primary source (peer-reviewed journal, trial registry, federal register) is linked; we have not independently re-extracted every figure.
- provider-reported: the claim traces to the provider's own published page.
- third-party-reported: the claim traces to a source url we could not attribute to the provider's own domain.
- unverified: no source url on file.
- not-covered: this provider does not offer the plan/medication in question.

## Provider pages
- /providers/nexlife/ — NexLife (compounded tirzepatide, compounded semaglutide)
- /providers/ro-body/ — Ro Body (GLP-1)
- /providers/hims-hers/ — Hims & Hers (GLP-1)
- /providers/mochi-health/ — Mochi Health (GLP-1)
- /providers/henry-meds/ — Henry Meds (GLP-1)
- /providers/found/ — Found (GLP-1)
- /providers/weightwatchers-clinic/ — WeightWatchers Clinic (GLP-1)
- /providers/plushcare/ — PlushCare (GLP-1)
- /providers/noom-med/ — Noom Med (GLP-1)
- /providers/eden/ — Eden (GLP-1)
- /providers/shed/ — Shed (GLP-1)
- /providers/enhance-md/ — Enhance.MD (GLP-1)
- /providers/oak-longevity/ — Oak Longevity (GLP-1)
- /providers/trimrx/ — TrimRx (GLP-1)
- /providers/medvi/ — MEDVi (GLP-1)
- /providers/bmimd/ — bmiMD (GLP-1)
- /providers/zappy-health/ — Zappy Health (GLP-1)
- /providers/calibrate/ — Calibrate (GLP-1)
- /providers/form-health/ — Form Health (GLP-1)
- /providers/ivim-health/ — IVIM Health (GLP-1)

## Research pages (each links its NCT/DOI primary source)
- /research/surmount-1/ — SURMOUNT-1: Tirzepatide in adults with obesity or overweight (NCT04184622)
- /research/surmount-3/ — SURMOUNT-3: Tirzepatide after intensive lifestyle intervention (NCT04657016)
- /research/surmount-4/ — SURMOUNT-4: Continued tirzepatide versus withdrawal for weight maintenance (NCT04660643)
- /research/surmount-5/ — SURMOUNT-5: Tirzepatide versus semaglutide, head to head (NCT05822830)
- /research/surmount-osa/ — SURMOUNT-OSA: Tirzepatide in obstructive sleep apnoea with obesity (NCT05412004)
- /research/summit-hfpef/ — SUMMIT: Tirzepatide in heart failure with preserved ejection fraction and obesity (NCT04847557)
- /research/tirzepatide-diabetes-prevention/ — SURMOUNT-1, three-year prediabetes analysis: Progression to type 2 diabetes (NCT04184622)
- /research/surpass-2/ — SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes (NCT03987919)
- /research/tirzepatide-lean-mass/ — Body-composition analyses: Lean mass change during tirzepatide treatment (no NCT)
- /research/tirzepatide-kidney-disease/ — Renal outcome analyses: Kidney endpoints with tirzepatide (no NCT)
- /research/tirzepatide-fatty-liver-mash/ — SYNERGY-NASH: Tirzepatide in MASH with fibrosis (no NCT)
- /research/tirzepatide-pcos/ — PCOS evidence base: Tirzepatide in polycystic ovary syndrome (no NCT)
- /research/tirzepatide-cardiovascular-outcomes/ — SURPASS-CVOT: Cardiovascular outcomes with tirzepatide (NCT04255433)
- /research/tirzepatide-type-2-diabetes/ — SURPASS programme: Glycaemic outcomes with tirzepatide (no NCT)
- /research/retatrutide-phase-3/ — Retatrutide (TRIUMPH programme): Retatrutide phase 3 results (no NCT)
- /research/attain-1/ — ATTAIN-1: Orforglipron for chronic weight management (no NCT)
- /research/oasis-4/ — OASIS 4: Oral semaglutide 25 mg for weight management (NCT05564117)
- /research/synergy-nash/ — SYNERGY-NASH: Tirzepatide for MASH with liver fibrosis (NCT04166773)

## Open data
/data/ — status page. Bulk exports are NOT yet offered: part of the
underlying dataset's reuse rights are still being confirmed, so no
open-data license is attached yet. /search-index.json (route metadata),
/feed.json, and /feed.xml are available now.

## Ranking methodology
/methodology/ — full 100-point rubric, category weights, and score caps
(e.g. no score above 70/100 with an undisclosed dispensing pharmacy).